CFI-400945 is not a selective cellular PLK4 inhibitor

Polo-like kinase 4 inhibition produces polyploidy and apoptotic death of lung cancers

(2018) Masanori Kawakami et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Inhibition of polo-like kinase 4 (PLK4): a new therapeutic option for rhabdoid tumors and pediatric medulloblastoma

(2017) Simone Treiger Sredni et al.   Oncotarget

53BP1 and USP28 mediate p53 activation and G1 arrest after centrosome loss or extended mitotic duration

(2016) Franz Meitinger et al.   JOURNAL OF CELL BIOLOGY

GOLPH3 drives cell migration by promoting Golgi reorientation and directional trafficking to the leading edge

(2016) Mengke Xing et al.   MOLECULAR BIOLOGY OF THE CELL

Actin- and microtubule-dependent regulation of Golgi morphology by FHDC1

(2016) Sarah J. Copeland et al.   MOLECULAR BIOLOGY OF THE CELL

Mitotic Golgi disassembly is required for bipolar spindle formation and mitotic progression

(2016) Gianni Guizzunti et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Reversible centriole depletion with an inhibitor of Polo-like kinase 4

(2015) Y. L. Wong et al.   SCIENCE

Polo-like Kinase 4 Inhibition: A Strategy for Cancer Therapy?

(2014) Andrew J. Holland et al.   CANCER CELL

Functional Characterization of CFI-400945, a Polo-like Kinase 4 Inhibitor, as a Potential Anticancer Agent

(2014) Jacqueline M. Mason et al.   CANCER CELL

Polo-like kinases: structural variations lead to multiple functions

(2014) Sihem Zitouni et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY